Myeloma News and Research

RSS
New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

John Theurer Cancer Center presents research findings at ASH meeting

John Theurer Cancer Center presents research findings at ASH meeting

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

No overall cancer risk in people who donate stem cells

No overall cancer risk in people who donate stem cells

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.